News

VIDEO: Treating Heart Failure Congestion Improved Hyperglycemia

Author and Disclosure Information

 

EXPERT ANALYSIS FROM ACC 15

References

SAN DIEGO – Congestion secondary to advanced heart failure appears to cause type 2 diabetes in a significant subgroup of patients, based on suggestive findings from a series of recently reported studies, Dr. Maya Guglin said during an interview at the annual meeting of the American College of Cardiology.

Dr. Guglin reviewed convergent findings from several groups of patients who received left ventricular assist devices to treat advanced heart failure. The analyses all showed that many, though not a majority, of those patients also had type 2 diabetes. Soon after patients received an assist device, the type 2 diabetes uniformly improved – and in many cases, glycemic control normalized.

Dr. Guglin, who has named this condition “cardiogenic diabetes,” said that reducing congestion with an assist device or with diuretic treatment seems the best way to both reduce congestion and improve or resolve the diabetes.

Those treatments will “improve quality of life, reduce hospital admissions for heart failure, and also improve the course of diabetes,” said Dr. Guglin, professor of medicine and medical director of the ventricular assist device program at the University of Kentucky in Lexington.

Dr. Guglin had no disclosures.

The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel.

Recommended Reading

Diabetes therapy and cardiac risk
Type 2 Diabetes ICYMI
More coronary artery calcification seen with sedentary behavior
Type 2 Diabetes ICYMI
Statins for all eligible under new guidelines could save lives
Type 2 Diabetes ICYMI
Apple’s ResearchKit
Type 2 Diabetes ICYMI
Eruptive xanthoma
Type 2 Diabetes ICYMI
Cardiovascular safety evidence for alogliptin reassuring
Type 2 Diabetes ICYMI
Anticipation runs high for coming megatrials in general cardiology
Type 2 Diabetes ICYMI
Poor control of CVD risk factors raises morbidity, mortality risk in diabetes
Type 2 Diabetes ICYMI
Heart failure spurs 'cardiogenic diabetes'
Type 2 Diabetes ICYMI
FDA panel reassured by saxagliptin’s CV safety data
Type 2 Diabetes ICYMI

Related Articles